A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma

Some cytogenetic abnormalities (CAs) are associated with poorer prognosis in multiple myeloma (MM); proteasome inhibitors appear to benefit patients with high-risk CAs. We evaluated 2247 MM patients from the TOURMALINE-MM1/-MM2/-MM3/-MM4 trials to assess the PFS benefit of ixazomib plus lenalidomide...

Descripción completa

Detalles Bibliográficos
Autores principales: Chng, Wee-Joo, Lonial, Sagar, Morgan, Gareth J., Iida, Shinsuke, Moreau, Philippe, Kumar, Shaji K., Twumasi-Ankrah, Philip, Villarreal, Miguel, Dash, Ajeeta B., Vorog, Alexander, Zhang, Xiaoquan, Suryanarayan, Kaveri, Labotka, Richard, Dimopoulos, Meletios A., Rajkumar, S. Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834310/
https://www.ncbi.nlm.nih.gov/pubmed/36631458
http://dx.doi.org/10.1038/s41408-022-00768-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834310/
https://www.ncbi.nlm.nih.gov/pubmed/36631458
http://dx.doi.org/10.1038/s41408-022-00768-5

Ejemplares similares